Navigation Links
Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
Date:7/3/2012

SAN DIEGO, July 3, 2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq:  TROV), a developer of trans-renal molecular diagnostics, announced today that they will be collaborating with The University of Texas MD Anderson Cancer Center on the detection of transrenal KRAS mutations in the urine of patients with pancreatic cancer.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

According to recent estimates KRAS mutations are present in more than 90% of pancreatic cancers (1-3), and in 23% of all cancer tissue samples examined by the Sanger Centre (4). An earlier publication in this field used a complicated two-stage PCR assay to detect KRAS mutations in the urine of patients with pancreatic carcinomas (5). Recently, Trovagene successfully completed the analytical development of digital PCR assays for the detection of the most prevalent KRAS mutations, including ones that account for approximately 95% of the KRAS mutations found in pancreatic adenocarcinomas, the most common form of pancreatic cancer. 

Matthew H. Katz, MD, FACS, who will lead the study for MD Anderson, said, "We are pleased to begin this study to detect KRAS mutations in the urine of patients with pancreatic cancer. We will also determine the KRAS mutation status from biopsies taken from the same patients. This will allow an early comparison of mutation detection using biopsy, which samples only a portion of a tumor, with detection using urine, a systemic sampling of the patient."

"The reliable detection and quantification of both KRAS mutations and wild type molecules from urine could eventually lead to a sensitive method for staging tumors before treatment and detecting minimal residual disease after treatment," said Dr. Charlie Rodi, chief technology officer at Trovagene. He added, "The volume of urine that can be collected far outstrips what is available by biopsy or even through blo
'/>"/>

SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
2. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
3. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
4. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
5. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
6. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
7. Shingles Vaccine is Safe, According to New Study
8. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... CITY, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced that results from the  IAP310 study ... Pain Medicine (RAPM), a peer-reviewed journal with ... Phase 3 trial evaluating the safety and efficacy ... sublingual tablet system (SSTS), for the treatment of ...
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( ... pulmonology, today announced completion of enrollment in their RENEW ... Clinical Study is the FDA-approved IDE pivotal trial for ... emphysema. It was anticipated that the study, ... 2013, would take until the end of 2014 to ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... 22, 2014 Although there are only 24 hours ... many people who have trouble finding time within their busy schedules ... for long periods of time to get in shape. Here are ... on the go. , Change Up Your Commute , Consider ... to add some exercise into your daily routine. If you must ...
(Date:10/22/2014)... 22, 2014 Richard Carlson, Managing Partner ... leader with over 25 years experience. Mr. Carlson ... the areas related to EDI, B2B Commerce, RFID and ... Editorial Advisory Board member for Pharmaceutical Commerce Magazine and ... Fin Group is a management and technology consulting firm ...
(Date:10/22/2014)... Reinberg HealthDay Reporter , TUESDAY, ... weight and length may be showing a genetic propensity for ... certain genes have been linked to increased body fat, but ... and lean muscle, the researchers said. At 1 year, ... ages 2 and 3, however, these genes were linked to ...
(Date:10/22/2014)... 2014 (HealthDay News) -- Two sisters in high school ... Ilina and Medha Krishen use electronic stethoscopes, which ... trouble in breathing patterns or heartbeats. Ilina, a ... wanted to find a way to detect early lung ... an electronic stethoscope, Ilina recorded one breath cycle each ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... Feb. 10 SilverCensus.com Inc. ( http://www.silvercensus.com ), ... healthcare professionals, announced today its expansion to a ... a Foundation that aims to revolutionize the way ... are a comprehensive senior living and senior healthcare ...
... Myeloma and Bone Cancer Research (IMBCR) have uncovered a ... within tumors.LOS ANGELES, Feb. 10 IMBCR researchers uncovered ... their own blood supply. Recent studies have shown that ... now show that PTN produced by tumor cells in ...
... AVC-Intra encoding, 64-bit support, seamless integration and improved quality ... MainConcept GmbH, a wholly-owned subsidiary of DivX, Inc. ... world,s leading providers of video/audio codecs and software development ... today announced the release of Codec SDK 8.0 with ...
... Technique Breast-Specific Gamma Imaging (BSGI) Resulting in Record ... Technologies, Inc., a leader in molecular breast imaging, ... the strongest fourth quarter in the company,s history. ... sales from 2007 to 2008 as molecular breast ...
... Feb. 10 Arete Therapeutics Inc. today,announced the initiation ... orally-,administered soluble epoxide hydrolase (s-EH) inhibitor being developed for,the ... involved in the metabolism,of arachidonic acid, a key signaling ... "Our AR9281 Phase II clinical trial ...
... Feb. 10 - Zeus, Inc. announces new product name changes that ... unaltered in composition and processing. They remain the same quality products ... , New brand names are as follows: , ... New trademarked product Aeos (TM), formerly known as ...
Cached Medicine News:Health News:SilverCensus.com Launches National Website for Caregivers, Senior Citizens, Healthcare Professionals 2Health News:Researchers Identify Novel Mechanism That Make Cancer Tumors Grow 2Health News:MainConcept Releases New Codec SDK 8.0 2Health News:MainConcept Releases New Codec SDK 8.0 3Health News:MainConcept Releases New Codec SDK 8.0 4Health News:Dilon Technologies Leads Molecular Breast Imaging Expansion 2Health News:Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes 2Health News:Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes 3Health News:Zeus Announces Product Name Changes 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: